[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
Rinsho Ketsueki
; 53(1): 92-6, 2012 Jan.
Article
en Ja
| MEDLINE
| ID: mdl-22374531
ABSTRACT
A 59-year-old woman was admitted to our hospital with jaundice, renal dysfunction, anemia and hypercalcemia. Primary plasma cell leukemia (PCL) was diagnosed based on findings of IgA-λ type M-protein, 22% plasma cells in the bone marrow and 23.1% plasma cells of WBC in the peripheral blood. Because the total bilirubin (T.Bil) level increased even after the administration of prednisolone (PSL), dexamethasone and methylprednisolone, the patient was started on bortezomib (0.7 mg/m(2) on days 1, 4, 8 and 11 for 3 weeks) combined with PSL (40 mg/day). The level of T.Bil decreased and the patient's condition remarkably improved. We then increased the dose of bortezomib to 1.0 mg/m(2) in the second course, but discontinued treatment just after starting the third course because NCI-CTCAE Grade 3 peripheral neuropathy developed. According to the criteria of the International Myeloma Working Group, the response category was VGPR (=very good partial response) at 1 month after pausing treatment. We recommend these novel agents for PCL, which is an aggressive form of extramedullary plasma cell cancer.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Ácidos Borónicos
/
Leucemia de Células Plasmáticas
/
Hiperbilirrubinemia
/
Antineoplásicos
Límite:
Female
/
Humans
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2012
Tipo del documento:
Article